Literature DB >> 31494402

Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study.

Khashayar Dashtipour1, Zoltan Mari2, Joseph Jankovic3, Charles H Adler4, Marc Schwartz5, Mitchell F Brin6.   

Abstract

OBJECTIVE: To determine the minimal clinically important change (MCIC) on Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) scores using data from Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE), which captured real-world practices and outcomes.
METHODS: Changes in the baseline TWSTRS scores (point and percentage changes) were compared to changes in the Patient and Clinician Global Impression of Change (PGIC and CGIC) ratings. Using logistic regression, the discrimination of the model was determined.
RESULTS: Among the 479 patients who completed all TWSTRS assessments, the mean TWSTRS Total score significantly decreased from baseline (39.2) to the final visit (27.1) (P < .0001). TWSTRS Total score point changes that compared with PGIC assessments "very much improved," "much improved" or better, and "minimally improved" or better were -11, -9, and -8, respectively, and were similar to previously published changes (ie, a decrease of ≥10 points). TWSTRS Total score data met indicators of good cutoffs for discrimination of the model including ≥70% percentage of outcomes correctly classified when compared with PGIC ratings. The TWSTRS Total score mapped to PGIC and CGIC ratings better than any TWSTRS subscale score.
CONCLUSIONS: The MCIC for improvement was ≥8 points based on mean TWSTRS Total scores in patients with cervical dystonia when compared against the patient-based evaluation of benefit (PGIC).
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CD PROBE; Cervical dystonia; Clinical effectiveness; OnabotulinumtoxinA

Mesh:

Substances:

Year:  2019        PMID: 31494402     DOI: 10.1016/j.jns.2019.07.031

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  4 in total

1.  OnabotulinumtoxinA Dosing, Disease Severity, and Treatment Benefit in Patients With Cervical Dystonia: A Cohort Analysis From CD PROBE.

Authors:  Pinky Agarwal; Richard Barbano; Henry Moore; Marc Schwartz; Aleksej Zuzek; Marjan Sadeghi; Atul Patel
Journal:  Front Neurol       Date:  2022-06-30       Impact factor: 4.086

2.  Head tremor in cervical dystonia: Quantifying severity with computer vision.

Authors:  Jeanne P Vu; Elizabeth Cisneros; Ha Yeon Lee; Linh Le; Qiyu Chen; Xiaoyan A Guo; Ryin Rouzbehani; Joseph Jankovic; Stewart Factor; Christopher G Goetz; Richard L Barbano; Joel S Perlmutter; Hyder A Jinnah; Sarah Pirio Richardson; Glenn T Stebbins; Rodger Elble; Cynthia L Comella; David A Peterson
Journal:  J Neurol Sci       Date:  2022-01-22       Impact factor: 4.553

3.  The Effect of Low Dose OnabotulinumtoxinA on Cervical Dystonia in Hypermobile Ehlers-Danlos Syndrome.

Authors:  Tina J Wang; Antonio Stecco; Khashayar Dashtipour
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2021-10-25

4.  Impact of abobotulinumtoxinA on the clinical features of cervical dystonia in routine practice.

Authors:  Richard M Trosch; Vijay P Misra; Pascal Maisonobe; Savary Om
Journal:  Clin Park Relat Disord       Date:  2020-06-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.